Women's Health: Breast Cancer Treatment

Wednesday, October 16, 2024, 12:00 PM - Friday, October 15, 2027, 11:59 AM, On Demand

In this episode, we will discuss breast cancer treatment with Dr. Melinda Telli, Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. We will delve into the natural history of and treatment options for DCIS (a non-invasive form of breast cancer), including the ongoing debate in the medical community regarding treatment vs. observation for low grade DCIS. We will cover staging of invasive breast cancer, and delve into treatment options including surgical options, radiation therapy, hormone therapy, chemotherapy, and biologic therapies. This episode will provide guidance on interpreting pathology reports for breast lesions, delivering a breast cancer diagnosis, and supporting patients undergoing breast cancer treatments including managing symptoms of anti-estrogen therapies.  Lastly, we will cover cancer survivorship care, and review how to monitor for recurrence in our breast cancer survivors in the primary care setting. 

AMA PRA Category 1 Credits™ (1.25 hours), Non-Physician Participation Credit (1.25 hours)

1. Determine if surgery, radiation, chemotherapy, and immunotherapy should be used in combination to treat breast cancer, depending on the stage and type of tumor.
2. Counsel patients about their breast cancer diagnosis and develop a treatment plan based on each patients risk factors, type of cancer and prognosis.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 1.25 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography
1.American Cancer Society. (2021). Treating Breast Cancer. American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/treatment.html 
2.American College of Obstetricians and Gynecologists, The. (2022). Breast Cancer Survivorship: Health and Fertility After Treatment. The American College of Obstetricians and Gynecologists, Frequently Asked Questions. https://www.acog.org/womens-health/faqs/breast-cancer-survivorship-health-and-fertility-after-treatment 
3.Cortesi, L., Rugo, H. S., & Jackisch, C. (2021). An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Targeted oncology, 16(3), 255–282. https://doi.org/10.1007/s11523-021-00796-4 
4.Marquez, L., Bonar, S., & Benford, D. (2024). 3 Breast cancer treatment innovations to look for in 2024. City of Hope. https://www.cityofhope.org/3-breast-cancer-treatment-innovations-to-look-for-in-2024 
5.Susan G. Komen. (2024). Emerging Areas in Metastatic Breast Cancer Treatment. The Susan G. Komen Breast Cancer Foundation. https://www.komen.org/breast-cancer/metastatic/emerging-areas/ 
6.Wiginton, K., & Nazario, B. (ed.). (2023). Family History and Triple-Negative Breast Cancer: What to Know. WebMD. https://www.webmd.com/breast-cancer/features/family-history-mtnbc-breast-cancer 

For activity related questions, please contact
     Name: Emily Manche
     Title: CME Compliance Coordinator
     Email: [email protected]

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.